Verenigde Staten - Engels - NLM (National Library of Medicine)

r-zero systems, inc. - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - antiseptic • hand sanitizer to decrease bacteria on the skin • recommended for repeated use • for use when soap and water are not available

Verenigde Staten - Engels - NLM (National Library of Medicine)

r-zero systems, inc. - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - antiseptic • hand sanitizer to decrease bacteria on the skin • recommended for repeated use • for use when soap and water are not available

Verenigde Staten - Engels - NLM (National Library of Medicine)

vertex pharmaceuticals incorporated - tezacaftor (unii: 8rw88y506k) (tezacaftor - unii:8rw88y506k), ivacaftor (unii: 1y740ill1z) (ivacaftor - unii:1y740ill1z) - tezacaftor 100 mg - symdeko is indicated for the treatment of cystic fibrosis (cf) in patients age 6 years and older who are homozygous for the f508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (cftr ) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence [see clinical pharmacology (12.1) and clinical studies (14)] . if the patient's genotype is unknown, an fda-cleared cf mutation test should be used to detect the presence of a cftr mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use. none. risk summary there are limited and incomplete human data from clinical trials and postmarketing reports on the use of symdeko or its individual components, tezacaftor and ivacaftor, in pregnant women to inform a drug-associated risk. although there are no animal reproduction studies with the concomitant administration of tezacaftor and ivacaftor, separate reproductive

Israël - Engels - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor; tezacaftor - film coated tablets - ivacaftor 150 mg; tezacaftor 100 mg - ivacaftor and tezacaftor - symdeko is a combination of tezacaftor and ivacaftor, indicated for the treatment of patients with cystic fibrosis (cf) aged 12 years and older who are homozygous for the f508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence.if the patient’s genotype is unknown, a health authority cleared cf mutation test should be used to detect the presence of a cftr mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.

Israël - Engels - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor; tezacaftor - film coated tablets - ivacaftor 150 mg; tezacaftor 100 mg - ivacaftor and tezacaftor - symdeko is a combination of tezacaftor and ivacaftor, indicated for the treatment of patients with cystic fibrosis (cf) aged 12 years and older who are homozygous for the f508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence.if the patient’s genotype is unknown, a health authority cleared cf mutation test should be used to detect the presence of a cftr mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.

Tanzania - Engels - Tanzania Medicinces & Medical Devices Authority

kepro bv, the netherlands - ivermectin - solution - 10mg

Tanzania - Engels - Tanzania Medicinces & Medical Devices Authority

kepro bv, the netherlands - ivermectin - solution for injection

Tanzania - Engels - Tanzania Medicinces & Medical Devices Authority

kepro bv, the netherlands - chlortetracycline - water soluble powder - 200 mg

Israël - Engels - Ministry of Health

vertex pharmaceuticals (u.k) limited, israel - ivacaftor; ivacaftor; tezacaftor - film coated tablets - ivacaftor 75 mg; tezacaftor 50 mg; ivacaftor 75 mg - ivacaftor and tezacaftor - symdeko is a combination of tezacaftor and ivacaftor, indicated for the treatment of patients with cystic fibrosis (cf) age 6 years and older who are homozygous for the f508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence.if the patient’s genotype is unknown, a health authority cleared cf mutation test should be used to detect the presence of a cftr mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - ivacaftor 150mg;  ;  ; tezacaftor 100mg;  ;  ; ivacaftor 150mg - film coated tablet - active: ivacaftor 150mg     tezacaftor 100mg     excipient: croscarmellose sodium hypromellose hypromellose acetate succinate magnesium stearate microcrystalline cellulose opadry yellow 20a120010 sodium laurilsulfate active: ivacaftor 150mg excipient: carnauba wax colloidal silicon dioxide croscarmellose sodium hypromellose acetate succinate lactose monohydrate magnesium stearate microcrystalline cellulose opacode black s-1-17823 opadry blue 85f90614 sodium laurilsulfate - symdeko is indicated for the treatment of patients with cystic fibrosis (cf) aged 12 years and older who are homozygous for the f508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence.